Research, Select, & Monitor Tuesday, January 22, 2019 7:06:09 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

Ticker Lookup
Alkermes, Inc.$34.14$.32.95%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Alkermes, Inc. vs Drug Delivery

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Innovative companies whose purpose is to design and develop new ways to introduce drugs to the body. These new methods may consist of time-released capsules, differing injection techniques, or enabling certain drugs to be taken orally that may not have been to be taken so before. Their revenue is obtained from selling their technology to pharmaceutical companies or licensing it to manufacturers of prescription drugs.
 Totals Company Industry
  Sales: N/A $7,581.5 Mil
  Market Cap: $5,304.7 Mil $379,732.0 Mil
  Analysts Recommendation: Buy Buy

 Averages Company Industry
  Historic Revenue: N/A 4.1%
  Estimated Revenue: N/A 20.6%
  Historic Earnings: N/A 9.7%
  Estimated Earnings: N/A 27.3%
  Stock Price (1 Year): (39.2%) 51.6%
  Cash per Share: N/A 4.2%
  Dividend: N/A N/A
  Trailing PE: N/A N/A
  Forward PE: N/A 17.9
  Price-to-Sales: N/A N/A
  Price-to-Book: N/A 3.8
  Dividend Yield: N/A N/A
  Market Cap: $5,304.7 Mil $29,210.2 Mil
  Net Margin: N/A 7.8%
  Gross Margin: N/A 60.1%
  Return on Equity: N/A .1
  Return on Assets: N/A .0
  Balance Sheet
  Current Ratio: N/A 1.9
  Quick Ratio: N/A 1.5
  Cash Ratio: N/A .7
  Debt-to-Equity: N/A .7
  Interest Coverage: N/A 2.3
  Relative-Strength Index: 58.1 N/A

 Other companies in Drug Delivery Price Market Cap
  Roche Holding AG  (RHHBY) $32.61 $222,250.8 Mil
  Sanofi  (SNY) $41.48 $104,035.6 Mil
  Eisai Co Ltd  (ESALY) $80.88 $23,182.3 Mil
  Nektar Therapeutics  (NKTR) $46.20 $7,996.8 Mil
  Dr. Reddys Laboratories Ltd.  (RDY) $37.04 $6,142.3 Mil

Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results, the logo, and News Selects are trademarks of
Copyright © 1998 - 2019 All rights reserved.